6 days ago
Eli Lilly launches Mounjaro KwikPen for diabetes treatment in India
Synopsis
Eli Lilly has launched Mounjaro in KwikPen, a prefilled pen for weekly administration, in India to treat type 2 diabetes and obesity. Priced from Rs 14,000, it offers personalized treatment with six dose strengths. Mounjaro, a dual GIP and GLP-1 receptor agonist, is a prescription-only medication to be used under medical supervision.
Reuters US pharmaceutical major Eli Lilly on Wednesday launched its blockbuster diabetes drug Mounjaro in KwikPen, a single patient use prefilled pen designed for once weekly administration-in the Indian market, intensifying competition with rival Danish drugmarker Novo pen will be available in six dose strengths and the price starts from Rs 14,000 for 2.5 mg dose, Rs 17,500 for 5 mg, Rs 22,000 for 7.5 mg and 10 mg and Rs 27,500 for 12.5 mg and 15 mg company said this will allow healthcare professionals to personalize treatment plans to better suit individual patient needs.
'The launch of Mounjaro KwikPen marks a step forward in the care of type 2 diabetes and obesity, offering a more convenient approach to medication administration." said Winselow Tucker, President and General Manager, Lilly India. 'We believe this innovation will support healthcare professionals in delivering more personalized and effective treatment plans, helping to improve outcomes and advance the quality of care for people living with these serious diseases.' The company has warned against the cosmetic use, reiterating that Mounjaro is a prescription-only medication and must be used strictly under the supervision of a qualified healthcare professional. 'It is not approved for—and must not be used for—cosmetic weight loss'.
'Patients are advised to consult their healthcare professional to determine whether Mounjaro is appropriate for their individual needs,' it further is the first and only dual GIP (glucose- dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist, indicated as an adjunct to diet and exercise for the treatment of Type 2 diabetes and chronic weight management in adults with obesity or overweight, with one weight-related in March the company launched Mounjaro in 2.5 mg vial and 5 mg vial at Rs 3500 and Rs 4375 respectively. Nearly half of India's 101 million adult patients with diabetes are inadequately treated with suboptimal glycemic control.
Mounjaro reduces body weight and decreases fat mass by regulating appetite.
